Rambler's Top100

ФОРУМ "ТРУДНЫЕ ДЕТИ"





Форум временно законсервирован, причины смотри здесь.

Теперь доктор Лев Пережогин осуществляет бесплатные онлайн-консультации на своем персональном сайте drlev.ru



ТРУДНЫЕ ДЕТИ > ФОРУМ

Lack of efficacy of citalopram in children with autism

 
Тема закрыта    Список форумов Трудные дети -> Обзор журналов и короткие научные сообщения
Автор Сообщение
drLev
Доктор


Зарегистрирован: 23.03.2004
Сообщения: 1483
Откуда: Москва

Добавлено: Пт Июл 10, 2009 7:59 am    Заголовок сообщения: Lack of efficacy of citalopram in children with autism

текст Arch Gen Psychiatry. 2009 Jun;66(6):583-90.
комментарий Arch Gen Psychiatry. 2009 Jun;66(6):581-2.

Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism.

King BH, Hollander E, Sikich L, McCracken JT, Scahill L, Bregman JD, Donnelly CL, Anagnostou E, Dukes K, Sullivan L, Hirtz D, Wagner A, Ritz L;
STAART Psychopharmacology Network.
Collaborators (4Cool
Affeldt R, Ambler D, Anderson G, Andresen ML, Baranek G, Bartz J, Bearss K, Bethea TC, Cowen J, Cronin P, DeRamus M, Dimino R, Ellison T, Feirsen N, Fenelon L, Gordon A, Halpern D, Houser MB, Jones C, Kaplan L, Kartheiser P, Keske R, Kim YS, Koenig K, Kustan E, Lapp K, Maerlender A, McDonald B, McQuade D, Nichols S, Nikolov R, Pachler M, Quinn E, Ramirez I, Richards J, Robichaux P, Robinson F, Rusoff J, Shah B, Soorya L, Spritzer L, Swanson E, Tripp T, Vidaver J, Waldoks S, Wang T, Wasserman S, Williams E.

Seattle Children's Hospital, University of Washington, 4800 Sand Point Way NE, Seattle, WA 98105, USA. bhking@u.washington.edu

CONTEXT: Selective serotonin reuptake inhibitors are widely prescribed for children with autism spectrum disorders. OBJECTIVES: To determine the efficacy and safety of citalopram hydrobromide therapy for repetitive behavior in children with autism spectrum disorders. DESIGN: National Institutes of Health-sponsored randomized controlled trial. SETTING: Six academic centers, including Mount Sinai School of Medicine, North Shore-Long Island Jewish Health System, University of North Carolina at Chapel Hill, University of California at Los Angeles, Yale University, and Dartmouth Medical School. PARTICIPANTS: One hundred forty-nine volunteers 5 to 17 years old (mean [SD] age, 9.4 [3.1] years) were randomized to receive citalopram (n = 73) or placebo (n = 76). Participants had autistic spectrum disorders, Asperger disorder, or pervasive developmental disorder, not otherwise specified; had illness severity ratings of at least moderate on the Clinical Global Impressions, Severity of Illness Scale; and scored at least moderate on compulsive behaviors measured with the Children's Yale-Brown Obsessive Compulsive Scales modified for pervasive developmental disorders. INTERVENTIONS: Twelve weeks of citalopram hydrobromide (10 mg/5 mL) or placebo. The mean (SD) maximum dosage of citalopram hydrobromide was 16.5 (6.5) mg/d by mouth (maximum, 20 mg/d). MAIN OUTCOME MEASURES: Positive response was defined by a score of much improved or very much improved on the Clinical Global Impressions, Improvement subscale. An important secondary outcome was the score on the Children's Yale-Brown Obsessive Compulsive Scales modified for pervasive developmental disorders. Adverse events were systematically elicited using the Safety Monitoring Uniform Report Form. RESULTS: There was no significant difference in the rate of positive response on the Clinical Global Impressions, Improvement subscale between the citalopram-treated group (32.9%) and the placebo group (34.2%) (relative risk, 0.96; 95% confidence interval, 0.61-1.51; P > .99). There was no difference in score reduction on the Children's Yale-Brown Obsessive Compulsive Scales modified for pervasive developmental disorders from baseline (mean [SD], -2.0 [3.4] points for the citalopram-treated group and -1.9 [2.5] points for the placebo group; P = .81). Citalopram use was significantly more likely to be associated with adverse events, particularly increased energy level, impulsiveness, decreased concentration, hyperactivity, stereotypy, diarrhea, insomnia, and dry skin or pruritus. CONCLUSION: Results of this trial do not support the use of citalopram for the treatment of repetitive behavior in children and adolescents with autism spectrum disorders.
Trial Registration clinicaltrials.gov Identifier: NCT00086645.

если нужен полный текст статьи, он тут: http://archpsyc.ama-assn.org/cgi/content/full/66/6/583
_________________
Консультации д.м.н. Пережогина Л. О. (drLev) http://www.drlev.ru/help.php
Эта тема закрыта    Список форумов Трудные дети -> Обзор журналов и короткие научные сообщения

Rambler's Top100 Рейтинг@Mail.ru